Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Biotechnology

Healthcare
$1.56 +3.16%

+$0.05 today

Market cap
$66.94M
Beta
1.91
P/E (TTM)
-0.8
EPS (TTM)
-$2.00
52W Low $1.15High $3.56

Volume 0.61M

Average 0.60M

ACRV Total Debt

Short-term and long-term borrowings combined.

Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 31.3% from a year ago

Total debt stood at $2.42M at the end of Q1 FY2026, down 31.3% from a year earlier and down 10.9% from the prior quarter. Over 3 fiscal years it compounded at -18.3% a year.

Context

  • Total debt amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -31.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.42M-10.9% QoQ
Last fiscal yearDec 2025
$2.71M-25.7% YoY
Year agoMar 2025
$3.51M-31.3% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.3%——
1 year-25.7%——
3-year CAGR-18.3%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
2.71M USD
Year-over-year change
-25.7%
4-year CAGR
-16.7%

Total Debt vs competitors

How ACRV compares with its peers on the latest reported figures

  • ACRV's Mar 2026 total debt of $2.42M is the 5th highest of the 10 companies compared; the peer median is $1.24M.
  • Its year-over-year change of -31.3% is the 5th highest of 9, against a peer median of -31.3%.
  • Total debt amounts to 2.2% of total assets for ACRV, versus a peer median of 2.7%.
ACRV Competitors Peer median
Total Debt for ACRV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CBUSCibus, Inc.Mar 2026$276.15M +674.7%+168.1%85.2%
TCRXTScan Therapeutics, Inc.Mar 2026$92.54M -4.6%+3.1%45.8%
ATYRaTyr Pharma, Inc.Mar 2026$11.7M -9.9%+1.4%14.7%
VXRTVaxart, Inc.Mar 2026$7.97M -52.6%-31.1%4.4%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$2.42M -31.3%-18.3%2.2%
BMEABiomea Fusion, Inc.Mar 2026$1.24M -84.4%-11.4%2.7%
UNCYUnicycive Therapeutics, Inc.Mar 2026$941K +35.6%-0.3%1.5%
IMUXImmunic, Inc.Mar 2026$421K -56.8%-24.1%0.2%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$293K -73.5%-60.9%0.3%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ACRV) $1.24M-31.3%-5.9%2.7%

Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents99.6M29.52M36.02M39.82M41.5M
Short-term Investments098.23M91.44M139.66M77.08M
Net Receivables00000
Inventory00000
Other Current Assets04.34M2.23M2.15M1.86M
Total Current Assets100.41M132.1M129.69M181.63M120.45M
Property, Plant & Equipment (Net)5.79M6.86M7.91M8.03M7.42M
Goodwill00000
Intangible Assets00000
Long-term Investments041.88M05.09M0
Tax Assets00000
Other Non-current Assets388K388K665K1.85M1.86M
Total Non-current Assets6.18M49.13M8.57M14.96M9.27M
Total Assets106.59M181.23M138.27M196.59M129.72M
Account Payables964K904K5.05M758K2.28M
Short-term Debt0001.06M0
Tax Payables00000
Deferred Revenue66K69K000
Other Current Liabilities667K2.66M3.86M5.46M5.56M
Total Current Liabilities2.91M6.52M13.3M17.21M15.66M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities122.52M0000
Total Non-current Liabilities127.48M4.24M3.77M2.59M1.54M
Total Liabilities130.4M10.75M17.07M19.8M17.2M
Common Stock2K22K23K31K31K
Retained Earnings(24.87M)(56.03M)(116.42M)(196.98M)(274.88M)
Accumulated OCI0(95K)(83K)447K111K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(23.81M)170.48M121.2M176.79M112.52M
Total Debt5.63M4.96M4.64M3.65M2.71M
Net Debt(93.98M)(24.56M)(31.37M)(36.17M)(38.79M)

Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Intrinsic Alpha fair value

Locked

Current Price

$1.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.